PT3177599T - Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória - Google Patents
Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatóriaInfo
- Publication number
- PT3177599T PT3177599T PT157595703T PT15759570T PT3177599T PT 3177599 T PT3177599 T PT 3177599T PT 157595703 T PT157595703 T PT 157595703T PT 15759570 T PT15759570 T PT 15759570T PT 3177599 T PT3177599 T PT 3177599T
- Authority
- PT
- Portugal
- Prior art keywords
- fumarate
- analogs
- treatment
- disease
- autoimmune disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033023P | 2014-08-04 | 2014-08-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3177599T true PT3177599T (pt) | 2020-03-05 |
Family
ID=54062798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157595703T PT3177599T (pt) | 2014-08-04 | 2015-07-31 | Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9475781B2 (pt) |
| EP (1) | EP3177599B1 (pt) |
| JP (2) | JP6735729B2 (pt) |
| CN (1) | CN106573901B (pt) |
| CA (1) | CA2956788A1 (pt) |
| DK (1) | DK3177599T3 (pt) |
| ES (1) | ES2775433T3 (pt) |
| PT (1) | PT3177599T (pt) |
| WO (1) | WO2016022434A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3177599B1 (en) * | 2014-08-04 | 2019-12-04 | Rigel Pharmaceuticals, Inc. | Fumarate analogs and uses thereof in the treatment of an autoimmune disease or an inflammatory disease |
| JP7202184B2 (ja) | 2016-02-03 | 2023-01-11 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｎｒｆ２活性化化合物およびその使用 |
| CN108699011B (zh) | 2016-02-03 | 2022-05-06 | 参宿七制药股份有限公司 | Nrf2活化性化合物及其用途 |
| JP2021523197A (ja) * | 2018-05-16 | 2021-09-02 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Ｎｒｆ２活性化化合物のプロドラッグおよびその使用 |
| CN114982379A (zh) | 2020-01-20 | 2022-08-30 | 株式会社小糸制作所 | 点亮电路以及车辆用方向指示灯 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501370D0 (en) * | 1995-01-24 | 1995-03-15 | Exxon Chemical Patents Inc | Additive concentrate |
| JPH08259547A (ja) * | 1995-03-20 | 1996-10-08 | Nippon Bayeragrochem Kk | 除草性１−アルケニルテトラゾリノン類 |
| MX2011001341A (es) | 2008-08-19 | 2011-03-29 | Xenoport Inc | Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso. |
| EP3159331A1 (en) * | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| EP3177599B1 (en) * | 2014-08-04 | 2019-12-04 | Rigel Pharmaceuticals, Inc. | Fumarate analogs and uses thereof in the treatment of an autoimmune disease or an inflammatory disease |
| CA2974900A1 (en) * | 2015-01-26 | 2016-08-04 | Rigel Pharmaceuticals, Inc. | Tetrazolones as carboxylic acid bioisosteres |
-
2015
- 2015-07-31 EP EP15759570.3A patent/EP3177599B1/en active Active
- 2015-07-31 US US14/815,589 patent/US9475781B2/en active Active
- 2015-07-31 DK DK15759570.3T patent/DK3177599T3/da active
- 2015-07-31 JP JP2017505614A patent/JP6735729B2/ja not_active Expired - Fee Related
- 2015-07-31 WO PCT/US2015/043279 patent/WO2016022434A1/en active Application Filing
- 2015-07-31 ES ES15759570T patent/ES2775433T3/es active Active
- 2015-07-31 CA CA2956788A patent/CA2956788A1/en active Pending
- 2015-07-31 CN CN201580044515.4A patent/CN106573901B/zh active Active
- 2015-07-31 PT PT157595703T patent/PT3177599T/pt unknown
-
2016
- 2016-09-19 US US15/269,233 patent/US9801866B2/en active Active
-
2017
- 2017-09-21 US US15/711,754 patent/US10493066B2/en not_active Expired - Fee Related
-
2019
- 2019-10-14 US US16/600,873 patent/US11129819B2/en active Active
-
2020
- 2020-03-25 JP JP2020053593A patent/JP6965390B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3177599B1 (en) | 2019-12-04 |
| JP2020114844A (ja) | 2020-07-30 |
| WO2016022434A1 (en) | 2016-02-11 |
| DK3177599T3 (da) | 2020-03-09 |
| CA2956788A1 (en) | 2016-02-11 |
| US10493066B2 (en) | 2019-12-03 |
| JP2017523978A (ja) | 2017-08-24 |
| US20170065569A1 (en) | 2017-03-09 |
| US20160039773A1 (en) | 2016-02-11 |
| CN106573901A (zh) | 2017-04-19 |
| US9801866B2 (en) | 2017-10-31 |
| US20200155531A1 (en) | 2020-05-21 |
| JP6965390B2 (ja) | 2021-11-10 |
| CN106573901B (zh) | 2021-03-02 |
| JP6735729B2 (ja) | 2020-08-05 |
| EP3177599A1 (en) | 2017-06-14 |
| US11129819B2 (en) | 2021-09-28 |
| US20180071271A1 (en) | 2018-03-15 |
| US9475781B2 (en) | 2016-10-25 |
| ES2775433T3 (es) | 2020-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283086A (en) | Use of cannabidiol in the treatment of multiple sclerosis complex | |
| IL281793A (en) | Use of cannabinoids in the treatment of epilepsy | |
| PT3240554T (pt) | Blautia stercosis e wexlerae para uso no tratamento de doenças inflamatórias e autoimunes | |
| PL3157512T3 (pl) | Zastosowanie kannabidioli w leczeniu padaczki | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| HK1245658A1 (zh) | 可用於治療ibd患者的營養組合物 | |
| ZA201704726B (en) | Peptides and their use in the treatment of skin | |
| IL251904B (en) | Epilimod for use in the treatment of melanoma | |
| SG11201701493VA (en) | Systems level state characteristics in experimental treatment of disease | |
| GB201417163D0 (en) | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | |
| PL3160464T3 (pl) | 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych | |
| PT3177599T (pt) | Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória | |
| HK1209351A1 (en) | Use of haemophilus parainfluenzae in the treatment or prevention of rheumatoid arthritis or related diseases | |
| HK1209359A1 (en) | Use of megamonas hypermegale in the treatment or prevention of rheumatoid arthritis or related diseases | |
| GB2537783B (en) | Compositions used in treating inflammatory and autoimmune diseases | |
| GB201418809D0 (en) | Therapeutic agents and uses thereof | |
| HK1209363A1 (en) | Use of lactobacillus crispatus in the treatment or prevention of rheumatoid arthritis or related diseases | |
| IL247207B (en) | Use of pericalcitol in the treatment of inflammatory anemia | |
| HK1209369A1 (en) | Use of alistipes shahii in the treatment or prevention of rheumatoid arthritis or related diseases | |
| HK1209368A1 (en) | Use of prevotella maculosa in the treatment or prevention of rheumatoid arthritis or related diseases | |
| GB201421888D0 (en) | Peptides derived from mysoin 19 and methods of use thereof | |
| IL250244B (en) | Prevention and treatment of inflammatory skin diseases | |
| GB201511772D0 (en) | Improvements in the treatment of ash | |
| HK1209356A1 (en) | Use of sutterella wadsworthensis in the treatment or prevention of rheumatoid arthritis or related diseases |